Read by QxMD icon Read

Chronic Myeloid Leukemia

shared collection
4 papers 0 to 25 followers
Katia Borgia Barbosa Pagnano, Israel Bendit, Carla Boquimpani, Carmino Antonio De Souza, Eliana C M Miranda, Ilana Zalcberg, Irene Larripa, Luciana Nardinelli, Rosana Antunes Silveira, Laura Fogliatto, Nelson Spector, Vaneuza Funke, Ricardo Pasquini, Vania Hungria, Carlos Sérgio Chiattone, Nelma Clementino, Monika Conchon, Elena Beatriz Moiraghi, Jose Luis Lopez, Carolina Pavlovsky, Miguel A Pavlovsky, Eduardo E Cervera, Luis Antonio Meillon, Belinda Simões, Nelson Hamerschlak, Alicia Helena Magarinos Bozzano, Ernesto Mayta, Jorge Cortes, Raquel M Bengió
This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p = 0.07 and 47% vs. 72%, p = 0.03, respectively) and in those with the T315I mutation (p = 0.003 and p = 0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs...
2015: Cancer Investigation
Josu de la Fuente, André Baruchel, Andrea Biondi, Eveline de Bont, Marie-Françoise Dresse, Meinolf Suttorp, Frédéric Millot
Chronic myeloid leukaemia in children and young people is a relatively rare form of leukaemia that shows increased incidence with age and some evidence suggests that the molecular basis differs from that in adults. Significant advances in targeted therapy with the development and use in children of tyrosine kinase inhibitors and the ability to monitor and understand the prognostic significance of minimal residual disease by standardized molecular techniques has shifted the management of this condition from bone marrow transplantation as the main therapeutic modality to individualized treatment for each patient based on achieving specific milestones...
October 2014: British Journal of Haematology
Claude Preudhomme, Joëlle Guilhot, Franck Emmanuel Nicolini, Agnès Guerci-Bresler, Françoise Rigal-Huguet, Frederic Maloisel, Valérie Coiteux, Martine Gardembas, Christian Berthou, Anne Vekhoff, Delphine Rea, Eric Jourdan, Christian Allard, Alain Delmer, Philippe Rousselot, Laurence Legros, Marc Berger, Selim Corm, Gabriel Etienne, Catherine Roche-Lestienne, Virginie Eclache, François-Xavier Mahon, François Guilhot
BACKGROUND: Imatinib (400 mg daily) is considered the best initial therapy for patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase. However, only a minority of patients treated with imatinib have a complete molecular remission. METHODS: We randomly assigned 636 patients with untreated chronic-phase CML to receive imatinib alone at a dose of 400 mg daily, imatinib (400 mg daily) plus cytarabine (20 mg per square meter of body-surface area per day on days 15 through 28 of each 28-day cycle) or pegylated interferon (peginterferon) alfa-2a (90 μg weekly), or imatinib alone at a dose of 600 mg daily...
December 23, 2010: New England Journal of Medicine
Michele Baccarani, Giovanni Martinelli, Gianantonio Rosti, Elena Trabacchi, Nicoletta Testoni, Simona Bassi, Marilina Amabile, Simona Soverini, Fausto Castagnetti, Daniela Cilloni, Barbara Izzo, Antonio de Vivo, Emanuela Messa, Francesca Bonifazi, Angela Poerio, Simona Luatti, Emilia Giugliano, Daniele Alberti, Gianluca Fincato, Domenico Russo, Fabrizio Pane, Giuseppe Saglio
Since interferon-alpha and imatinib (IM; STI571, Glivec, Gleevec) are effective for the treatment of chronic myeloid leukemia (CML), and their mechanisms of action are different, we designed an exploratory study investigating the effects of a standard IM dose (400 mg/d) and a variable pegylated interferon-alpha (PegIFN) dose (50 microg/wk, 100 microg/wk, and 150 microg/wk). The criteria for dose adjustment were designed so as to ensure the delivery of the IM dose and to protect life quality. There were 76 patients with previously untreated Philadelphia (Ph)-positive CML enrolled in the study...
December 15, 2004: Blood
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"